Table 3. Changes in MoCA-K sub-items after treatment in study subjects.
| Measure | 0 week | 12 weeks | 28 weeks | p-value | |
|---|---|---|---|---|---|
| Visuospatial | 0.565 | ||||
| ALC | 2.8±1.4 | 2.9±1.4 | 3.0±1.3 | ||
| Placebo | 2.3±1.4 | 2.4±1.3 | 2.4±1.3 | ||
| Naming | 0.310 | ||||
| ALC | 2.5±0.7 | 2.5±0.8 | 2.5±0.8 | ||
| Placebo | 2.4±1.0 | 2.2±1.1 | 2.3±1.1 | ||
| Attention* | 0.025 | ||||
| ALC | 3.7±1.4 | 3.7±1.1 | 3.5±1.5 | ||
| Placebo | 4.1±1.7 | 3.5±1.3 | 3.3±1.3 | ||
| Language* | 0.012 | ||||
| ALC | 1.4±0.9 | 1.5±1.0 | 1.9±0.8 | ||
| Placebo | 1.3±0.8 | 1.8±1.0 | 1.5±0.7 | ||
| Abstract | 0.443 | ||||
| ALC | 0.8±0.6 | 0.9±0.8 | 0.9±0.6 | ||
| Placebo | 0.8±0.7 | 0.8±0.7 | 1.1±0.6 | ||
| Delayed recall | 0.100 | ||||
| ALC | 0.9±0.9 | 1.1±0.7 | 1.3±0.8 | ||
| Placebo | 1.2±1.0 | 1.2±0.9 | 1.2±0.9 | ||
| Orientation† | 0.000 | ||||
| ALC | 4.7±1.4 | 4.2±1.5 | 4.1±1.3 | ||
| Placebo | 4.3±1.3 | 4.0±1.4 | 3.8±1.3 | ||
MoCA-K: Korean version of Montreal Cognitive Assessment, ALC: Acetyl-L-carnitine.
*Statistically significant difference was found between ALC- and placebo-treated groups according to clinical trial follow-up; †Statistically significant difference was found according to clinical trial follow-up, but statistically significant group difference was not found.